Neurocrine - NBIX Enterprise Value-to-Revenue Multiple

Public company logo of Neurocrine Biosciences, Inc. (NBIX)

Neurocrine Biosciences (NBIX) generates a powerful cash flow thanks to Ingrezza, ensuring high profitability. Demand for unique neurological drugs is inelastic and crisis-resistant. Structural business growth funds new developments. The enterprise value-to-revenue ratio on GURU.Markets captures the capital momentum, where the 4023.80 metric reflects current dynamics, helping to avoid purchasing an overvalued asset at its peak.

Neurocrine Corp - NBIX EV/Sales Multiple (period 11/23/2025 - 11/21/2026)

NBIX (neurocrine.com): analytical breakdowns and indicator data

- share price and consensus valuation forecast:
Initial company analysis:NBIX (Neurocrine Biosciences)
Original product of Neurocrine Biosciences

The EV/Sales metric determines the total value of the business, including net debt, relative to the volume of generated sales, allowing for an assessment of asset monetization efficiency without distortions from the capital structure. Investors utilize this indicator to identify whether a company is overbought or undervalued compared to industry peers. Analyzing the business valuation of Neurocrine Biosciences (NBIX) through EV/Sales helps determine the extent to which the market currently prices in the success of Ingrezza and the potential of new neuroendocrinology drugs.

Competitor analysis for Neurocrine Biosciences

BIIB (Biogen Inc.) - Company Value to Revenue Ratio|RGC: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Axsome (AXSM)|Enterprise Value-to-Revenue Ratio ACADIA Pharmaceuticals Inc|Company Value to Revenue Xenon Pharmaceuticals Inc (XENE)|EV/Sales Multiple VKTX|EV/Sales Multiple supernus.com (SUPN)|Enterprise Value-to-Revenue Ratio Catalyst Pharmaceuticals, Inc. CPRX|DNLI (Denali Therapeutics Inc.) - Enterprise Value to Sales Volume|Harmony Corp - EV/Sales Multiple|BHVN: Enterprise Value-to-Revenue Ratio|AMLX: EV/Sales Multiple|TRVI: Enterprise Value-to-Revenue Coefficient|Enterprise Value-to-Revenue Ratio Praxis Medicines|Enterprise Value-to-Revenue Multiple Anavex AVXL|Enterprise Value-to-Revenue Ratio CeriBell Corp (CBLL)|Enterprise Value-to-Revenue Coefficient PRTA|EV/Sales Multiple ALEC (Alector)|Annexon (ANNX) - Enterprise Value-to-Revenue Multiple|OMER - Enterprise Value-to-Revenue Ratio|NGNE (Neurogene) - Company Value to Revenue Ratio|ACIU: EV/Sales Multiple|VYGR - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Neumora Therapeutics, Inc.|Company Value to Revenue Ratio SCLX (Scilex)|Company Value to Revenue TVGN (Tevogen Bio)|EV/Sales Multiple Alpha Cognition Inc (ACOG)|EV/Sales Multiple CGTX (cogrx.com)|Total Company Value-to-Revenue Ratio Inhibikase Pharma (IKT)|SAVA: Company Value to Revenue|Total Company Value-to-Revenue Ratio Assertio ASRT|COYA (coyatherapeutics.com) - Company Value to Revenue|Company Value to Revenue Ratio VTGN|OVID (Ovid Therapeutics) - EV/Sales Multiple|Acumen Pharmaceuticals, Inc (ABOS) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio CervoMed, Inc. (CRVO)|ATHE - Enterprise Value-to-Revenue Multiple|EV/Sales Multiple CLNN (Clene Inc.)|Total Company Value-to-Revenue Ratio PepGen Inc. (PEPG)|JUNS - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Relmada Corp|ANVS (Annovis Bio, Inc.) - Company Value to Revenue|Grace Tx (GRCE) - EV/Sales Multiple|Company Value to Revenue AIFF|EV/Sales Multiple anewmeds.com|Enterprise Value-to-Revenue Ratio NeuroSense Therapeutics (NRSN)|RVPH (Reviva Pharmaceuticals Holdings) - Business Value to Revenue|MetaVia - Company Value to Revenue|NRXS: Company Value to Revenue Ratio|Helius Medical Technologies, Inc. - EV/Sales Multiple|PASG: Enterprise Value-to-Revenue Ratio|Neuphoria (NEUP) - Enterprise Value-to-Revenue Ratio|Minerva Neurosciences - Business Value to Revenue|ATHA (Athira Pharma, Inc.) - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple addextherapeutics.com ADXN|Company Value to Revenue ALZN (Alzamend Neuro Inc.)|CYCN (Cyclerion Therapeutics, Inc.) - Business Value to Revenue|EV/Sales Multiple PTIX (Protagenic)|EV/Sales Multiple pasitheaclinics.com KTTA|CRGT - Enterprise Value-to-Revenue Ratio|Business Value to Revenue ATXI (Avenue Therapeutics)|BCLI: EV/Sales Multiple|Cara Therapeutics - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Chromocell Therapeutics Corporation|EV/Sales Multiple Eliem Therapeutics Inc.|Enterprise Value-to-Revenue Ratio Intra-Cellular Therapies, Inc. (ITCI)|LBPH (Longboard Pharmaceuticals) - Business Value to Revenue|EV/Sales Multiple MRNS (marinuspharma.com)|NKGN: Company Value to Revenue Ratio|NRBO - Enterprise Value-to-Revenue Ratio|SAGE - EV/Sales Multiple|Synaptogenix (SNPX) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Trevena (TRVN)|Company Value to Revenue VIGL|Company Value to Revenue Ratio WENA (Anew Medical)|EV/Sales Multiple CERE